Clearpoint Neuro Inc (CLPT)

$6.7

+0.11

(+1.67%)▲

Market is closed - opens 8 PM, 11 Dec 2023

Insights on Clearpoint Neuro Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 5.95M → 5.76M (in $), with an average decrease of 3.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -7.05M → -4.80M (in $), with an average increase of 46.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 18.9% return, outperforming this stock by 44.2%

Performance

  • $6.46
    $6.75
    $6.70
    downward going graph

    3.55%

    Downside

    Day's Volatility :4.26%

    Upside

    0.73%

    downward going graph
  • $4.05
    $11.00
    $6.70
    downward going graph

    39.55%

    Downside

    52 Weeks Volatility :63.18%

    Upside

    39.09%

    downward going graph

Returns

PeriodClearpoint Neuro IncSector (Health Care)Index (Russel 2000)
3 Months
25.0%
-0.7%
0.0%
6 Months
-7.07%
1.3%
0.0%
1 Year
-22.63%
-4.3%
-1.5%
3 Years
-63.71%
18.3%
-7.5%

Highlights

Market Capitalization
147.5M
Book Value
$0.98
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.89
Wall Street Target Price
9.5
Profit Margin
-97.92%
Operating Margin TTM
-84.99%
Return On Assets TTM
-27.33%
Return On Equity TTM
-68.33%
Revenue TTM
22.3M
Revenue Per Share TTM
0.91
Quarterly Revenue Growth YOY
12.0%
Gross Profit TTM
13.5M
EBITDA
-21.7M
Diluted Eps TTM
-0.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.93
EPS Estimate Next Year
-0.79
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Clearpoint Neuro Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 41.79%

Current $6.70
Target $9.50

Company Financials

FY17Y/Y Change
Revenue
7.4M
↑ 28.35%
Net Income
-7.2M
↓ 11.18%
Net Profit Margin
-97.12%
↑ 43.24%
FY18Y/Y Change
Revenue
7.4M
↓ 0.36%
Net Income
-6.2M
↓ 14.01%
Net Profit Margin
-83.82%
↑ 13.3%
FY19Y/Y Change
Revenue
11.2M
↑ 52.54%
Net Income
-6.5M
↑ 5.53%
Net Profit Margin
-57.98%
↑ 25.84%
FY20Y/Y Change
Revenue
12.8M
↑ 14.37%
Net Income
-9.1M
↑ 40.04%
Net Profit Margin
-71.0%
↓ 13.02%
FY21Y/Y Change
Revenue
16.3M
↑ 27.05%
Net Income
-15.3M
↑ 68.2%
Net Profit Margin
-93.99%
↓ 22.99%
FY22Y/Y Change
Revenue
20.6M
↑ 26.09%
Net Income
-16.5M
↑ 7.95%
Net Profit Margin
-80.47%
↑ 13.52%
Q2 FY22Q/Q Change
Revenue
5.2M
↑ 3.36%
Net Income
-4.4M
↑ 8.58%
Net Profit Margin
-84.65%
↓ 4.07%
Q3 FY22Q/Q Change
Revenue
5.1M
↓ 1.04%
Net Income
-3.8M
↓ 14.11%
Net Profit Margin
-73.47%
↑ 11.18%
Q4 FY22Q/Q Change
Revenue
5.2M
↑ 0.54%
Net Income
-4.3M
↑ 13.75%
Net Profit Margin
-83.13%
↓ 9.66%
Q1 FY23Q/Q Change
Revenue
5.4M
↑ 5.01%
Net Income
-5.4M
↑ 25.37%
Net Profit Margin
-99.25%
↓ 16.12%
Q2 FY23Q/Q Change
Revenue
6.0M
↑ 9.52%
Net Income
-7.1M
↑ 30.79%
Net Profit Margin
-118.52%
↓ 19.27%
Q3 FY23Q/Q Change
Revenue
5.8M
↓ 3.16%
Net Income
-4.8M
↓ 31.81%
Net Profit Margin
-83.46%
↑ 35.06%
FY17Y/Y Change
Total Assets
13.9M
↑ 87.78%
Total Liabilities
8.1M
↓ 1.08%
FY18Y/Y Change
Total Assets
7.9M
↓ 43.47%
Total Liabilities
6.3M
↓ 21.35%
FY19Y/Y Change
Total Assets
11.9M
↑ 51.8%
Total Liabilities
7.3M
↑ 15.66%
FY20Y/Y Change
Total Assets
29.6M
↑ 148.52%
Total Liabilities
27.3M
↑ 271.44%
FY21Y/Y Change
Total Assets
65.6M
↑ 121.26%
Total Liabilities
16.8M
↓ 38.4%
FY22Y/Y Change
Total Assets
55.5M
↓ 15.39%
Total Liabilities
18.6M
↑ 10.77%
Q2 FY22Q/Q Change
Total Assets
60.2M
↓ 2.47%
Total Liabilities
17.4M
↑ 8.62%
Q3 FY22Q/Q Change
Total Assets
57.7M
↓ 4.15%
Total Liabilities
17.9M
↑ 2.53%
Q4 FY22Q/Q Change
Total Assets
55.5M
↓ 3.89%
Total Liabilities
18.6M
↑ 4.16%
Q1 FY23Q/Q Change
Total Assets
50.2M
↓ 9.45%
Total Liabilities
17.7M
↓ 5.03%
Q2 FY23Q/Q Change
Total Assets
47.6M
↓ 5.19%
Total Liabilities
20.2M
↑ 14.51%
Q3 FY23Q/Q Change
Total Assets
43.8M
↓ 7.98%
Total Liabilities
19.7M
↓ 2.41%
FY17Y/Y Change
Operating Cash Flow
-6.0M
↑ 2.96%
Investing Cash Flow
-26.8K
↓ 73.51%
Financing Cash Flow
12.0M
↑ 213.28%
FY18Y/Y Change
Operating Cash Flow
-4.6M
↓ 22.73%
Investing Cash Flow
-63.5K
↑ 137.33%
Financing Cash Flow
-1.5M
↓ 112.46%
FY19Y/Y Change
Operating Cash Flow
-2.8M
↓ 38.46%
Investing Cash Flow
-160.0K
↑ 152.01%
Financing Cash Flow
5.6M
↓ 474.97%
FY20Y/Y Change
Operating Cash Flow
-7.8M
↑ 174.01%
Investing Cash Flow
-482.0K
↑ 201.25%
Financing Cash Flow
22.7M
↑ 304.92%
FY21Y/Y Change
Operating Cash Flow
-12.7M
↑ 62.62%
Investing Cash Flow
-168.0K
↓ 65.15%
Financing Cash Flow
46.9M
↑ 106.56%
FY22Y/Y Change
Operating Cash Flow
-16.2M
↑ 27.33%
Investing Cash Flow
-10.7M
↑ 6290.48%
Financing Cash Flow
409.0K
↓ 99.13%
Q2 FY22Q/Q Change
Operating Cash Flow
-5.0M
↑ 16.68%
Investing Cash Flow
-21.7M
↑ 11611.35%
Financing Cash Flow
513.0K
↑ 17000.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.9M
↓ 22.67%
Investing Cash Flow
-631.0K
↓ 97.09%
Financing Cash Flow
-329.0K
↓ 164.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.1M
↓ 20.43%
Investing Cash Flow
11.7M
↓ 1961.49%
Financing Cash Flow
222.0K
↓ 167.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.7M
↑ 85.32%
Investing Cash Flow
-138.0K
↓ 101.17%
Financing Cash Flow
-5.0K
↓ 102.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.1M
↓ 10.65%
Investing Cash Flow
9.5M
↓ 6991.3%
Financing Cash Flow
237.0K
↓ 4840.0%

Technicals Summary

Sell

Neutral

Buy

Clearpoint Neuro Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Clearpoint Neuro Inc
Clearpoint Neuro Inc
46.61%
-7.07%
-22.63%
-63.71%
-63.71%
Stryker Corporation
Stryker Corporation
2.58%
3.28%
16.03%
24.5%
68.41%
Dexcom, Inc.
Dexcom, Inc.
18.93%
-7.83%
0.16%
34.56%
280.3%
Boston Scientific Corp.
Boston Scientific Corp.
2.31%
7.32%
16.59%
63.54%
50.3%
Abbott Laboratories
Abbott Laboratories
9.1%
3.07%
-4.55%
-2.35%
45.48%
Medtronic Plc
Medtronic Plc
10.09%
-5.85%
-0.45%
-29.39%
-16.88%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Clearpoint Neuro Inc
Clearpoint Neuro Inc
NA
NA
NA
-0.93
-0.68
-0.27
0.0
0.98
Stryker Corporation
Stryker Corporation
44.25
44.25
2.89
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
128.52
128.52
2.39
1.43
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
68.46
68.46
1.75
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
35.67
35.67
25.14
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.97
25.97
1.61
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Clearpoint Neuro Inc
Clearpoint Neuro Inc
Buy
$147.5M
-63.71%
NA
-97.92%
Stryker Corporation
Stryker Corporation
Buy
$113.1B
68.41%
44.25
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$45.1B
280.3%
128.52
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$82.2B
50.3%
68.46
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$182.1B
45.48%
35.67
12.92%
Medtronic Plc
Medtronic Plc
Buy
$106.4B
-16.88%
25.97
12.84%

Institutional Holdings

  • BlackRock Inc

    5.58%

  • Vanguard Group Inc

    5.18%

  • Geode Capital Management, LLC

    1.74%

  • Taylor Frigon Capital Management LLC

    1.44%

  • Brown Advisory Holdings Inc

    1.35%

  • State Street Corporation

    1.33%

Corporate Announcements

  • Clearpoint Neuro Inc Earnings

    Clearpoint Neuro Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot

Organization
Clearpoint Neuro Inc
Employees
108
CEO
Mr. Joseph Michael Burnett
Industry
Health Technology

Discover More

FAQs